S&P Futures
4,542.50 +6.00 (+0.13%) Dow Futures
35,570.00 +13.00 (+0.04%) Nasdaq Futures
15,380.25 +39.25 (+0.26%) Russell 2000 Futures
2,287.10 -1.70 (-0.07%) Crude Oil
84.46 +0.70 (+0.84%) Gold
1,800.10 +3.80 (+0.21%)
Amgen Inc. (AMGN)
Pre-Market: 06:22AM EDT
Chart Events
Performance Outlook
| Previous Close | 208.99 |
| Open | 209.70 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 208.53 - 210.50 |
| 52 Week Range | 200.47 - 276.69 |
| Volume | 1,349,344 |
| Avg. Volume | 2,551,457 |
| Market Cap | 118.817B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 21.22 |
| EPS (TTM) | 9.86 |
| Earnings Date | Nov 02, 2021 |
| Forward Dividend & Yield | 7.04 (3.36%) |
| Ex-Dividend Date | Aug 16, 2021 |
| 1y Target Est | 247.45 |
Fair Value
Related Research
- Amgen Inc.Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).RatingFair ValueEconomic Moat14 days agoMorningstar
- PR Newswire
Amgen Announces 2021 Fourth Quarter Dividend
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will be paid on December 8, 2021, to all stockholders of record as of the close of business on November 16, 2021.
- Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit Amgen Inc (NASDAQ: AMGN) with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity. AstraZeneca's AZD5991 belongs to the same class therapy. The trial suspension, noted on ClinicalTrials.gov, came on October 19: "The study has been put on hold to allow further evaluation of safety-related information,"
- Benzinga
Race to Effective Psoriasis Treatment: Can-Fite's Piclidenoson May Edge Over High-Flying Amgen's Otezla. Here's Why
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Amgen Inc. (NASDAQ: AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla for the treatment of adults with mild to moderate plaque psoriasis. The company also said the FDA had set a Prescription Drug
